Skip to main content
Clinical Trials/NCT05750459
NCT05750459CompletedPhase 4

Exposure-Response Evaluation of IV Artesunate in Children With Severe Malaria

National Institute of Allergy and Infectious Diseases (NIAID)1 site in 1 country90 target enrollmentStarted: November 29, 2023Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
90
Locations
1
Primary Endpoint
Change from baseline diastolic blood pressure

Study Overview

Brief Summary

This clinical study is a phase 4, single-site, open-label pharmacokinetic (PK) study of IV artesunate in up to 100 Ugandan children 6 months-14 years of age who are diagnosed with severe malaria according to standardized World Health Organization (WHO) criteria (any P. falciparum parasitemia and the presence of danger signs). Participants will receive the standard of care IV artesunate for initial treatment of severe malaria per WHO guidelines: children weighing <20 kg should receive 3.0 mg/kg/dose compared to children weighing =20 kg who should receive 2.4 mg/kg/dose, at times 0, 12, 24, 48 and 72 hours (WHO 2015). Parenteral treatment will be administered for a minimum of 24 hours (irrespective of the patient's ability to tolerate oral medication earlier), after which patients will be evaluated clinically and assessed for ability for oral intake of antimalarials. Children who are able to transition to oral antimalarial therapy will initiate a 3-day course of artemisinin-combination oral therapy per national guidelines. The primary objective of the study is to determine the relationship between DHA exposures following IV artesunate dosing and markers of physiologic dysfunction associated with severe malaria in Ugandan children.

Detailed Description

This clinical study is a phase 4, single-site, open-label pharmacokinetic (PK) study of IV artesunate in up to 100 Ugandan children 6 months-14 years of age who are diagnosed with severe malaria according to standardized World Health Organization (WHO) criteria (any P. falciparum parasitemia and the presence of danger signs). Participants will receive the standard of care IV artesunate for initial treatment of severe malaria per WHO guidelines: children weighing <20 kg should receive 3.0 mg/kg/dose compared to children weighing =20 kg who should receive 2.4 mg/kg/dose, at times 0, 12, 24, 48 and 72 hours (WHO 2015). Parenteral treatment will be administered for a minimum of 24 hours (irrespective of the patient's ability to tolerate oral medication earlier), after which patients will be evaluated clinically and assessed for ability for oral intake of antimalarials. Children who are able to transition to oral antimalarial therapy will initiate a 3-day course of artemisinin-combination oral therapy per national guidelines. Biomarkers of physiologic dysfunction will be quantified at regular intervals, including serum lactate, serum glucose, total and direct bilirubin, bicarbonate levels, Blantyre Coma Score (BCS), creatinine and hemoglobin. These biomarkers will be considered both independently and together as a weighted score to relate to the PK of the active metabolite of IV artesunate, DHA and to efficacy markers that more accurately reflect clinical outcomes. We will also quantify P. falciparum parasitemia using standardized thick blood smear and relate this outcome to DHA dose and exposure for comparison with historical studies. Children 6 months to 14 years of age living in or near Tororo District, Uganda, who are diagnosed with severe malaria and who meet inclusion and exclusion criteria will be enrolled.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
6 Months to 14 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Children ages 6 months-14 years at the time of severe malaria diagnosis, inclusive
  • Meet the case definition for severe malaria, per WHO standardized guidelines
  • Parent/guardian willing to provide informed consent
  • Assent for children between 8 and 14 years who are conscious and otherwise able to provide assent, inclusive

Exclusion Criteria

  • 1. Receipt of > 24 hours of artemisinin therapy

Arms & Interventions

Arm 1

Experimental

Participants will receive the standard of care with IV artesunate for treatment of severe malaria. Each 60-mg vial of artesunic acid will be dissolved in 1 mL of 5% sodium bicarbonate to form sodium artesunate and then mixed with 5 mL of 5% dextrose. This will be injected as a bolus into an indwelling IV cannula. Children weighing <20 kg will receive IV artesunate at a dose of 3.0 mg/kg/dose compared to older children weighing >/= 20kg who will receive 2.4 mg/kg/dose, at times 0, 12, 24. If unable to take oral medication, IV artesunate will continue at 48 and 72 hours. Children who recover and are able to transition to oral antimalarial therapy after a minimum of 24 hours, will initiate a 3-day course of oral artemisinin-combination therapy per national guidelines. N = 100

Intervention: Artesunate (Drug)

Outcomes

Primary Outcomes

Change from baseline diastolic blood pressure

Time Frame: Day 1 through Day 183

Change from baseline in temperature.

Time Frame: Day 1 through Day 183

Change from baseline in total bilirubin

Time Frame: Day 1 through Day 183

Change from baseline bicarbonate levels

Time Frame: Day 1 through Day 183

Change from baseline creatinine.

Time Frame: Day 1 through Day 183

Change from baseline in Blantyre Coma Score (BCS).

Time Frame: Day 1 through Day 183

Change from baseline in direct bilirubin

Time Frame: Day 1 through Day 183

Change from baseline in concentration of Dihydroartemisinin (DHA)

Time Frame: Day 1

Pharmacokinetic parameters that will be derived from the concentration of Dihydroartemisinin (DHA) include maximum concentration (C max), area under the curve over hours 0-12 (AUC 0-12) and half-life (t 1/2) and time to C max (T max).

Change from baseline in hemoglobin

Time Frame: Day 1 through Day 183

Change from baseline in serum glucose

Time Frame: Day 1 through Day 183

Change from baseline systolic blood pressure

Time Frame: Day 1 through Day 183

Change from baseline in venous serum lactate.

Time Frame: Day 1 through Day 183

Secondary Outcomes

  • Parasite (P. falciparum) density in thick blood smear.(Day 1 through Day 5 minimum)
  • Time to hospital discharge.(Day 1 through 183)

Investigators

Sponsor Class
Nih
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials